<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122652</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-11</org_study_id>
    <nct_id>NCT03122652</nct_id>
  </id_info>
  <brief_title>Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome</brief_title>
  <acronym>TERIS</acronym>
  <official_title>Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a common cause of severe neurological disability in young adults,
      resulting from an autoimmune interruption of both myelin and axons within the central nervous
      system (CNS). The diagnosis is made by fulfilling both spatial criteria, by meeting the
      requisite number of lesions within the brain or spinal cord, along with criteria for time, by
      demonstrating a history of at least a second clinical attack or the development of a new MS
      lesion on MRI after the seminal neurological event. In the case of MS, healthy individuals
      who do not exhibit signs of neurological dysfunction commonly have brain MRI studies
      performed for a reason other than an evaluation for MS that reveal unexpected anomalies
      highly suggestive of demyelinating plaques given their size, location, and morphology. These
      healthy subjects lack symptomatology suggestive of MS and fulfill formal criteria for
      radiologically isolated syndrome (RIS), a recently described MS subtype that expands upon the
      phenotype of at-risk individuals for future demyelinating events. The discovery of such
      anomalies creates intersecting neuro-ethical, legal, social, and practical medical management
      quandaries and is, therefore, of both immediate and long-term clinical significance. Despite
      advancements in the characterization of RIS subjects, and in our understanding of risk
      factors for initial symptom development, the effect of treatment on such cases remain
      unclear.

      The purpose of this investigation is to systematically study the efficacy of Teriflunomide in
      those individuals who possess incidental white matter anomalies within the brain and
      following a MRI study that is performed for a reason other than for the evaluation of MS.

      RIS subjects are frequently exposed to disease modifying therapies despite the lack of
      scientific literature supporting the use of such treatments. Earlier treatment intervention
      may extend the time to the first acute or progressive clinical event resulting from CNS
      demyelination and reduce radiological progression. In addition, early treatment may result in
      more profound effects on reducing disability progression long-term.

      The primary outcome measure for this trial is the time to the first acute or progressive
      neurological event resulting from CNS demyelination.

      This study will include RIS subjects from the Europe who fulfill 2009 RIS Criteria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">September 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first acute or progressive neurological event resulting from CNS demyelination.</measure>
    <time_frame>Week 96</time_frame>
    <description>Acute neurological event: The development of an acute neurological episode localized to the optic nerve, brainstem, cerebellum, spinal cord, or long sensory or motor tracts, lasting &gt; 24 hours followed by a period of symptom improvement.
Progressive event: The onset of a clinical symptom (e.g. leg weakness) with the temporal profile revealing at least a 12-month progression of neurological deficits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or enlarging T2 lesions</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of new or enlarging T2 lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or enlarging T2 lesions</measure>
    <time_frame>Week 96</time_frame>
    <description>Number of new or enlarging T2 lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New contrast enhancing lesions</measure>
    <time_frame>Week 48</time_frame>
    <description>New contrast enhancing lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New contrast enhancing lesions</measure>
    <time_frame>Week 96</time_frame>
    <description>New contrast enhancing lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New T2-lesion volumes</measure>
    <time_frame>Week 48</time_frame>
    <description>New T2-lesion volumes on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New T2-lesion volumes</measure>
    <time_frame>Week 96</time_frame>
    <description>New T2-lesion volumes on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy</measure>
    <time_frame>Week 96</time_frame>
    <description>Brain atrophy on MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Terifunomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide 14 MG Oral Tablet [Aubagio]</intervention_name>
    <description>1 tablet once a day</description>
    <arm_group_label>Terifunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>1 tablet once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of all ages(&gt;18 years and &lt;65 years) meeting 2009 RIS criteria:

             A. The presence of incidentally identified CNS white matter anomalies meeting the
             following MRI criteria:

               1. Ovoid, well-circumscribed, and homogeneous foci observed with or without
                  involvement of the corpus callosum

               2. T2 hyperintensities measuring ≥3 mm and fulfilling Barkhof criteria (at least
                  three out of four) for dissemination in space

               3. Anomalies not following a clear vascular pattern

               4. Structural neuroimaging abnormalities identified not explained by another disease
                  process B. No historical accounts of remitting clinical symptoms consistent with
                  neurological dysfunction C. The MRI anomalies do not account for clinically
                  apparent impairments in social, occupational, or generalized area of functioning
                  D. The MRI anomalies are not due to the direct physiological effects of
                  substances (recreational drug use, toxic exposure) or a medical condition E.
                  Exclusion of individuals with MRI phenotypes suggestive of leukoaraiosis or
                  extensive white matter changes lacking clear involvement of the corpus callosum
                  F. The CNS MRI anomalies are not better accounted for by another disease process

          2. Identified RIS cases with the initial MRI demonstrating anomalies suggestive of
             demyelinating disease dated &gt; 2009

          3. Incidental anomalies identified on MRI of the brain or spinal cord with the primary
             reason for the acquired MRI resulting from an evaluation of a process other than MS

          4. Affiliation to the social security system

          5. Subjects of reproductive potential are eligible only if the following applies:

               -  Women of childbearing potential (WOCBP):Must have a negative serum pregnancy test
                  at Visit 1 (Screening) and negative urine pregnancy test at Visit 2 (Baseline);

               -  Must be agree to undertake 1 monthly urine pregnancy tests during the study and
                  up to 6 weeks after the first of two tests showing teriflunomide plasma level
                  &lt;0.02 mg/L;

               -  Must agree to use reliable methods of contraception from Visit 1 until 6 weeks
                  after the first oft wo tests showing teriflunomide plasma level &lt;0.02 mg/L.

        Fertile male subjects participating in the study who are sexually active with WOCBP:

        - Must agree to use condom during the treatment period and for an additional 6 weeks after
        the first oft wo tests showing teriflunomide plasma level &lt;0.02 mg/L.

        Exclusion Criteria:

          1. Hypersensitivity to the active substance or to any of the excipients listed in section
             6.1 of summary of product characteristics (SmPC).

          2. Patients with severe hepatic impairment (Child-Pugh class C).

          3. Patients with severe immunodeficiency states, e.g. AIDS.

          4. Patients with significantly impaired bone marrow function or significant anaemia,
             leucopenia, neutropenia or thrombocytopenia.

          5. Patients with severe active infection until resolution.

          6. Patients with severe renal impairment undergoing dialysis.

          7. Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.

          8. Lactating or pregnant women

          9. Subjects wishing to parent a child during the study

         10. Incomplete medical history or radiological data

         11. History of remitting clinical symptoms consistent with multiple sclerosis lasting &gt; 24
             hours prior to CNS imaging revealing anomalies suggestive of MS

         12. History of paroxysmal symptoms associated with MS (i.e. Lhermitte's or Uhthoff's
             phenomena)

         13. CNS MRI anomalies are better accounted for by another disease process

         14. The subject is unwilling or unable to comply with the requirements of the study
             protocol

         15. Exposure to a disease modifying therapy within the past 3 months

         16. Exposure to high-dose glucocorticosteroid treatment within the past 30 days

         17. Vulnerable subject (such as deprived from freedom) as defined in Section 1.61 of
             International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice
             (GCP: Individuals whose willingness to volunteer in a clinical trial may be unduly
             influenced by the expectation, whether justified or not, of benefits associated with
             participation, or of a retaliatory response from senior members of a hierarchy in case
             of refusal to participate. Examples are members of a group with a hierarchical
             structure, such as medical, pharmacy, dental, and nursing students, subordinate
             hospital and laboratory personnel, employees of the pharmaceutical industry, members
             of the armed forces, and persons kept in detention. Other vulnerable subjects include
             patients with incurable diseases, persons in nursing homes, unemployed or impoverished
             persons, patients in emergency situations, ethnic minority groups, homeless persons,
             nomads, refugees, minors, and those incapable of giving consent.)

         18. Participation in another clinical trial of an investigational medicinal product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cassandre LANDES</last_name>
    <phone>492034126</phone>
    <phone_ext>33</phone_ext>
    <email>landes.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra VUKUSIC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandra VUKUSIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine WIERTLEWSKI</last_name>
    </contact>
    <investigator>
      <last_name>Sandrine WIERTLEWSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandre LANDES</last_name>
      <phone>492034126</phone>
      <phone_ext>33</phone_ext>
      <email>landes.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Christine LEBRUN-FRENAY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric THOUVENOT</last_name>
    </contact>
    <investigator>
      <last_name>Eric THOUVENOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle LE PAGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle LE PAGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David BRASSAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>David BRASSAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens WÜRFEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jens WÜRFEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of the Ruhr - University Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten LUKAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carsten LUKAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte WILDEMANN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte WILDEMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenberg</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frauke ZIPP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frauke ZIPP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark MÜHLAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark MÜHLAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sten FREDERICKSEN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sten FREDERICKSEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludwig Kappos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ludwig Kappos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rana Karabudak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rana Karabudak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mustafa Kemal University</name>
      <address>
        <city>Antakya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taskin Duman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Taskin Duman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aksel Siva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aksel Siva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kocaeli University School of Medicine</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Husnu Efendi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Husnu Efendi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikos Evangelou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nikos Evangelou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

